Prevention of stroke in patients with nonvalvular atrial fibrillation

Neurology

Volumn 51, Issue 3, 1998, Pages 674-681

  Hart, Robert G ^a   Sherman, David G ^a   Easton, J Donald ^b   Cairns, John A ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ANTICOAGULATION; BLEEDING; COHORT ANALYSIS; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0031721749     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.3.674     Document Type: Review

References (63)

1. Boysen G, Nyboe J, Appleyard M, et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke 1988; 19:1345-1353.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987; 147:1561-1564.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.
4. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR. Short-term predictors of incident stroke in older adults: The Cardiovascular Health Study. Stroke 1996;27:1479-1486.
5. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized clinical trials. Arch Intern Med 1994;154:1949-1957.
6. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633-638.
7. European Atrial Fibrillation Trial Study Group. Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke. Lancet 1993;342:1255-1262.
8. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991;84:527-539.
9. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.
10. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-179.
11. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:1505-1511.
12. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355.
13. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
14. Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997;28: 1015-1021.
15. Hellemons BSP, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in patients with nonrheumatic atrial fibrillation in general practice (the PATAF study). Cerebrovasc Disord 1997;7(suppl 4):11. Abstract.
16. Harenberg J, Weuster B, Pfitzei M, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemostasis 1993; 19(suppl):116-121.
17. Gullov AL, Koefoed BG, Petersen P, et al. Mini-dose warfarin and aspirin in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation Study (AFASAK II). Arch Intern Med 1998;158:1513-1521.
18. Diener HC, Forbes C, Riekkinin PJ, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study II. Efficacy and safety data. J Neurol Sci 1997;151:S13-S17.
19. Diener HC, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. J Neurol Sci 1997;153:112. Letter.
20. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-473.
21. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-241.
22. Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and longterm prognosis. Br Med J 1992;305:1460-1465.
23. Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D'Agostino RB. Newly diagnosed atrial fibrillation and acute stroke: The Framingham Study. Stroke 1995;26:1527-1530.
24. Manolio TA, Burke GL, Psaty BM, et al. Black-white differences in subclinical cardiovascular disease among older adults: The Cardiovascular Health Study. J Clin Epidemiol 1995;48:1141-1152.
25. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med 1987;317:669-674.
26. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. J Am Med Assoc 1985; 254:3449-3453.
27. Kanter MC, Tegeler CH, Pearce LA, et al. Carotid stenosis inpatients with atrial fibrillation: prevalence, risk factors and relationship to stroke. Arch Intern Med 1994;154:1372-1377.
28. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation I: clinical features inpatients at risk. Ann Intern Med 1992;116:1-5.
29. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation II: echocardiographic features in patients at risk. Ann Intern Med 1991;1: 6-12.
30. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboemolism during aspirin therapy in atrial fibrillation. J Stroke Cerebrovasc Dis 1995;5:147-157.
31. Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. JAMA 1998;279:1273-1277.
32. Stroke Prevention in Atrial Fibrillation Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with atrial fibrillation. Ann Intern Med 1998;128:639-647.
33. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke inpatients with atrial fibrillation: a prospective study of 1,066 patients from three clinical trials. Arch Intern Med 1998;158:1316-1320.
34. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med 1997;157:1237-1240.
35. Connolly S. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:1509. Letter.
36. Green CJ, Hadorn DC, Bassett K, Kazanjian A. Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. Can J Cardiol 1997;13:811-815.
37. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
38. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897-902.
39. Vingerhoets F, Bogousslavsky J, Regli F, Van Melle G. Atrial fibrillation after acute stroke. Stroke 1993;24:26-30.
40. Sacco RL, Kargman DE, Zamanillo MC. Race-ethnic differences in stroke risk factors among hospitalized patients with cerebral infarction. Neurology 1995;45:659-663.
41. Worley KL, Lalonde DR, Kerr DR, Benavente O, Hart RG. Survey of the causes of stroke among Mexican Americans in South Texas. Texas Med 1998;94:62-67.
42. Klatsky AL, Armstrong MA, Friedman GD. Racial differences in cerebrovascular disease hospitalizations. Stroke 1991;22: 299-304.
43. Lindgren A, Roijer A, Norrving B, Wallin L, Eskilsson J, Johansson BB. Carotid artery and heart disease in subtypes of cerebral infarction. Stroke 1994;25:2356-2362.
44. Bogousslavsky J, VanMelle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with atrial fibrillation: The Lausanne Stroke Registry. Neurology 1990;40:1046-1050.
45. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology 1993;43:32-36.
46. Hinton RC, Kistler P, Fallon JR, Friedlich AL, Fisher CM. Influence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol 1977;40:509-513.
47. Shively BK, Gelgand EA, Crawford MH. Regional left atrial stasis during atrial fibrillation and flutter: determinants and relation to stroke. J Am Coll Cardiol 1996;27:1722-1729.
48. Jones EF, Calafiore P, McNeil JJ, Tonkin AM, Donnan GA. Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke. Am J Cardiol 1996;78:425-429.
49. Laupacis A, Albers GW, Dalen JE, Dunn MI, Feinberg W, Jacobsen AK. Antithrombotic therapy in atrial fibrillation. Chest 1995;108(suppl):352S-359S.
50. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Dose efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-1953.
51. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy for atrial fibrillation. Arch Intern Med 1996;156:411-416.
52. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-979.
53. Hart RG, Boop B, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypothesis. Stroke 1995;26: 1471-1477.
54. Hart RG. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation. Ann Intern Med 1998;128:408. Letter.
55. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5-10.
56. Hylek EM, Skates SA, Singer DE. Anticoagulation for nonrheumatic atrial fibrillation. N Engl J Med 1997;336:442. Letter.
57. Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators. Atrial fibrillation follow-up investigation of rhythm management - The AFFIRM Study design. Am J Cardiol 1997;79:1198-1202.
58. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemic of presumed arterial origin. Ann Neurol 1997;42:857-865.
59. Man-Son-Hing M, Laupacis A, O'Connor A, Wells G. Warfarin for atrial fibrillation: the patient perspective. Arch Intern Med 1996;156:1841-1848.
60. Gage BF, Cardinalli AB, Owen DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-1836.
61. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995: 274:1839-1845.
62. Publications Committee for the TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke. JAMA 1998;279:1265-1272.
63. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischemic stroke. Lancet 1997;349:1569-1581.